FBIO vs. VSTM, BOLT, SPPI, MACK, XOMA, RIGL, XLO, VBIV, RVPH, and VTVT
Should you be buying Fortress Biotech stock or one of its competitors? The main competitors of Fortress Biotech include Verastem (VSTM), Bolt Biotherapeutics (BOLT), Spectrum Pharmaceuticals (SPPI), Merrimack Pharmaceuticals (MACK), XOMA (XOMA), Rigel Pharmaceuticals (RIGL), Xilio Therapeutics (XLO), VBI Vaccines (VBIV), Reviva Pharmaceuticals (RVPH), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical preparations" industry.
Fortress Biotech vs.
Verastem (NASDAQ:VSTM) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.
Fortress Biotech has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.
Verastem has a net margin of 0.00% compared to Fortress Biotech's net margin of -117.49%. Fortress Biotech's return on equity of -54.56% beat Verastem's return on equity.
Verastem has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500.
Verastem currently has a consensus price target of $4.25, suggesting a potential upside of 924.10%. Fortress Biotech has a consensus price target of $6.00, suggesting a potential upside of 700.00%. Given Verastem's higher possible upside, research analysts plainly believe Verastem is more favorable than Fortress Biotech.
In the previous week, Verastem had 6 more articles in the media than Fortress Biotech. MarketBeat recorded 12 mentions for Verastem and 6 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.05 beat Verastem's score of -0.03 indicating that Fortress Biotech is being referred to more favorably in the news media.
Verastem received 269 more outperform votes than Fortress Biotech when rated by MarketBeat users. However, 67.38% of users gave Fortress Biotech an outperform vote while only 66.55% of users gave Verastem an outperform vote.
60.6% of Verastem shares are owned by institutional investors. Comparatively, 27.9% of Fortress Biotech shares are owned by institutional investors. 2.9% of Verastem shares are owned by company insiders. Comparatively, 26.3% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Fortress Biotech beats Verastem on 9 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Fortress Biotech Competitors List